Pharmafile Logo

U3 Pharma

Diversity icons in Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why diversity matters…

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Cuttsy + Cuttsy

- PMLiVE

ICR researchers reveal how advanced breast cancers become resistant to hormone therapy

F404 mutations combined with pre-existing mutations caused resistance to fulvestrant

Digital icon inside Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why digital matters…

Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.

Cuttsy + Cuttsy

- PMLiVE

UK government approves digital pathology for cancer screening programmes

The approval follows a study that showed digital pathology was as effective as microscopy

- PMLiVE

BioNTech and Autolus enter CAR-T cell therapy collaboration worth over $250m

Both companies will leverage their autologous CAR-T cell therapy programmes

- PMLiVE

Academics and industry collaborate to advance precision therapy in breast cancer

The AI-based clinical study is funded by a grant worth almost £800,000 from Innovate UK

- PMLiVE

Novartis expands oncology pipeline with €2.7bn MorphoSys acquisition

The deal includes an investigational therapy being evaluated in myelofibrosis

- PMLiVE

WHO reveals growing global cancer burden in line with World Cancer Day

The three most commonly occurring cancers in 2022 were lung, breast and colorectal cancer

- PMLiVE

Advancing Patient-Centered Cancer Care Through Education to #CloseTheCareGap

One of the next frontiers in oncology isn’t being explored in a lab. Instead, it’s advancing in hospitals and private clinics around the world, thanks to the hard work of...

Medscape Education Global

- PMLiVE

AbbVie announces NICE recommendation for blood cancer therapy Tepkinly

Around 5,500 new cases of diffuse large B-cell lymphoma are diagnosed in the UK every year

- PMLiVE

Sobi receives NICE recommendation for Zynlonta in two non-Hodgkin lymphomas

Over 10,000 people are diagnosed with a type of non-Hodgkin lymphoma every year in the UK

- PMLiVE

New microscopy technique could help diagnose and treat brain tumours

The high-resolution imaging method reveals new cells and structures in human brain tissue

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links